Header

UZH-Logo

Maintenance Infos

BAP1 missense mutations in cancer: friend or foe?


Okonska, Agata; Felley-Bosco, Emanuela (2019). BAP1 missense mutations in cancer: friend or foe? Trends in Cancer, 5(11):659-662.

Abstract

BRCA-associated protein-1 (BAP1) is mutated in several cancers and a few therapies targeting BAP1 loss-of-function mutations have been proposed, some of them being already tested in clinical trials. However, most of the missense mutations have not been functionally characterized, although such information is essential for successful patient stratification.

Abstract

BRCA-associated protein-1 (BAP1) is mutated in several cancers and a few therapies targeting BAP1 loss-of-function mutations have been proposed, some of them being already tested in clinical trials. However, most of the missense mutations have not been functionally characterized, although such information is essential for successful patient stratification.

Statistics

Citations

Dimensions.ai Metrics
1 citation in Web of Science®
1 citation in Scopus®
Google Scholar™

Altmetrics

Downloads

7 downloads since deposited on 07 Feb 2020
7 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Thoracic Surgery
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Health Sciences > Oncology
Life Sciences > Cancer Research
Language:English
Date:November 2019
Deposited On:07 Feb 2020 17:55
Last Modified:29 Jul 2020 13:59
Publisher:Elsevier
ISSN:2405-8033
OA Status:Green
Publisher DOI:https://doi.org/10.1016/j.trecan.2019.09.006
PubMed ID:31735283

Download

Green Open Access

Content: Published Version
Language: English
Filetype: PDF - Registered users only
Size: 1MB
View at publisher
Download PDF  'BAP1 missense mutations in cancer: friend or foe?'.
Preview
Content: Accepted Version
Filetype: PDF
Size: 927kB
Licence: Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)